
The Drug Enforcement Administration Friday proposed limiting telehealth prescriptions for buprenorphine and other controlled substances after the COVID-19 public health emergency to a 30-day supply unless the prescriber or referring clinician have evaluated the patient in person. DEA will accept comments on the proposed rules for 30 days after their publication in the Federal Register.